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Estrogen receptor-α (ERα) is a steroid hormone-sensitive transcription factor that plays
a critical role in development of breast cancer. The binding of estrogen to ERα triggers
the recruitment of transcriptional co-activators as well as chromatin remodeling factors to
estrogen-responsive elements (ERE ) of ERα target genes. This process is tightly associ-
ated with post-translational modifications (PTMs) of ERα and its co-activators for promotion
of transcriptional activation, which leads to proliferation of a large subset of breast tumor
cells. These PTMs include phosphorylation, acetylation, methylation, and conjugation by
ubiquitin and ubiquitin-like proteins. Ubiquitin-fold modifier 1 (UFM1), one of ubiquitin-like
proteins, has recently been shown to be ligated to activating signal co-integrator 1 (ASC1),
which acts as a transcriptional co-activator of nuclear receptors. Here, we discuss the
mechanistic connection between ASC1 modification by UFM1 and ERα transactivation,
and highlight how the interplay of these processes is involved in development of breast
cancer. We also discuss potential use of UFM1-conjugating system as therapeutic targets
against not only breast cancer but also other nuclear receptor-mediated cancers.
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INTRODUCTION
Protein modifications by ubiquitin and ubiquitin-like proteins,
including SUMO and ISG15, have emerged as critical regulatory
processes, such as in the control of cell cycle, stress response, signal-
ing transduction, and immune response. Moreover, deregulation
of the modification systems often gives rise to numerous human
diseases, such as cancers, neurodegenerative diseases, and immune
diseases (1–4).
Ubiquitin-fold modifier 1 (UFM1) is the most recently identi-
fied ubiquitin-like protein (5). Like ubiquitination, protein mod-
ification by UFM1 (ufmylation) utilizes a cascade three-enzyme
system: UBA5 as an UFM1-activating E1 enzyme, UFC1 as an
UFM1-conjugating E2 enzyme, and UFL1 as an UFM1 E3 lig-
ase. This ufmylation process can be reversed by UFM1-specific
proteases (UFSPs) (6). All of the proteins involved in reversible
protein modification by UFM1 are conserved in metazoa and
plants,but not in yeast, implicating its specific roles in multicellular
organisms.
Abbreviations: AR, androgen receptor; ASC1, activating signal co-integrator 1;
Cdk5rap3, CDK5 regulatory subunit-associated protein 3; DDRGK1, DDRGK
domain-containing protein 1, ERα, estrogen receptor-α; ISG15, interferon-
stimulated gene 15; LZAP, LXXLL/leucine zipper-containing alternative reading
frame (ARF)-binding protein; Maxer, multiple α–helix protein located at ER;
NCAM, neuronal cell adhesion molecule; NLBP, novel LZAP-binding protein;
RARα, retinoic acid receptor α; RCAD, regulator of C53/LZAP and DDRGK1; SRC1,
steroid receptor coactivator 1; SUMO, small ubiquitin-related modifier; TRIP4,
thyroid hormone receptor interactor 4; UBA, ubiquitin-like modifier activating
enzyme; UBE1DC1, ubiquitin activating enzyme E1-domain containing 1; UFBP1,
UFM1-binding protein 1 containing a PCI domain; UFC1, ubiquitin-fold modifier-
conjugating enzyme 1; UFL1, UFM1-specific ligase 1; UFM1, ubiquitin-fold
modifier 1; UFSP, UFM1-specific protease; Urm1, ubiquitin-related modifier 1.
Not only estrogen receptor α (ERα) itself but also its co-
regulators, including SRC1 and p300, are known to undergo a
wide variety of post-translational modifications (PTMs), such
as phosphorylation, acetylation, methylation, ubiquitination, and
sumoylation. Moreover, these PTMs have been identified as critical
events that regulate the expression of ERα and its transcriptional
co-regulators and their stability, subcellular localization, and sen-
sitivity to hormonal response (7–12). Although the components
of estrogen signaling pathways are suitable and efficient targets for
breast cancer therapies, the role of their PTMs in initiation and
progression of breast carcinogenesis remains largely elusive.
Activating signal co-integrator 1 (ASC1), originally identified
as thyroid hormone receptor interactor 4 (TRIP4), is one of ERα
transcriptional co-activators (13). It also serves as a co-activator
of other nuclear receptors, such as thyroid hormone receptor
(TR) and retinoic acid receptor α (RARα) (14–16). However,
it remained unknown whether ASC1 also undergoes PTMs and
how the PTMs of ASC1 influence its co-activator function toward
nuclear receptors.
In this review, we will provide an overview on current and
emerging roles of the UFM1 system, with a focus on ASC1 ufmy-
lation in regulation of breast cancer development. A thorough
understanding of ASC1 ufmylation would promote not only the
identification of new markers for prognosis of breast cancer but
also the development of novel therapeutic strategies.
PROPERTIES OF UFM1
UFM1 consists of 85 amino acids with a predicted molecular mass
of 9.1 kDa. Its gene is located in human chromosome 13q13.3.
UFM1 is expressed in human cells as a precursor with a C-terminal
Ser-Cys dipeptide extension,which needs to be processed by UFSPs
www.frontiersin.org March 2015 | Volume 6 | Article 36 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yoo et al. UFM1 in breast cancer growth
FIGURE 1 | 3D structures of ubiquitin and UFM1 in human. PDB IDs for
ubiquitin and UFM1 are 1UBQ and 1WXS, respectively.
prior to conjugation to target proteins (5). Matured UFM1 has a
single glycine residue at the C-terminus, which also is required for
conjugation to its target proteins, unlike ubiquitin and most other
ubiquitin-like proteins, such as SUMO and NEDD8, which have
a conserved C-terminal di-glycine. UFM1 is localized in both the
nucleus and the cytoplasm (5).
Although UFM1 has a limited amino acid sequence iden-
tity (~16%) with ubiquitin, it displays a striking similarity in
its tertiary structure to ubiquitin (Figure 1). UFM1 adopts an
ubiquitin-like α+ β fold with ordered β−β−α−β−β−α−β sec-
ondary structure along the sequence (17). A special feature in
UFM1 structure is the absence of the cluster of the acidic residues
in the α1 surface, which is displayed by ubiquitin (17). Therefore,
it has been suggested that UFM1 employs the uncharged surface
for binding to its putative partners.
ENZYMES FOR UFM1 MODIFICATION
UBA5
UBA5 (also known as UBE1DC1), an UFM1-activating E1
enzyme, consists of 404 amino acids with a predicted molecu-
lar mass of 44.7 kDa (18). Its gene is located in human chro-
mosome 3q22.1. UBA5 is expressed in human as two distinct
isoforms (amino acid sequences: 1–404 and 57–404) due to alter-
native splicing of its primary transcript (19, 20). The role of
the additional N-terminal region (1–56) is unknown, as it is not
required for UFM1 activation (19). Typically, E1 enzymes consist
of the first and second catalytic cysteine half-domains (FCCH and
SCCH, respectively), the adenylation domain, and the C-terminal
ubiquitin-fold domain (19). UBA5 lacks the FCCH and SCCH
domains, but instead simply comprises an adenylation domain, in
which the catalytic cysteine (Cys250) is located, and an ubiquitin-
fold domain (19, 20). Therefore, UBA5 is much smaller than other
E1 enzymes, which comprise >1,000 amino acid residues. UBA5
is predominantly localized in the cytoplasm (20).
At the expense of ATP, UBA5 activates UFM1 (i.e., generates
adenylated UFM1 and inorganic pyrophosphate). UFM1 is then
conjugated to Cys250 of UBA5 via a thioester bond with the release
of AMP (5). It has been reported that UBA5 can also activate
SUMO2 under both in vitro and in vivo conditions (20). How-
ever, the loss of mouse UBA5 has no effect on the conjugation of
ubiquitin-like proteins to cellular proteins, except that of UFM1
(21). In addition, overexpression of UBA5 promotes the modifi-
cation of ASC1 by UFM1, but not by any other ubiquitin-like pro-
teins (22), indicating that UBA5 is a specific E1 enzyme for UFM1.
Significantly, UBA5-deficient mice die in utero due to severe
anemia associated with defective differentiation of both megakary-
ocytes and erythrocytes, although UBA5 is dispensable for the
production of erythropoietin (21). Moreover, transgenic expres-
sion of UBA5 in the erythroid lineage rescues the UBA5-deficient
embryos from anemia and prolongs their survival, revealing that
the UFM1-conjugating system has an essential role in erythroid
differentiation. However, it is necessary to clarify whether UBA5
has other functions distinct from protein conjugation in the con-
trol of erythrocyte biogenesis in mice, as UBA4, the E1 enzyme of
the Urm1 system, is known to function in tRNA uracyl thiolation
in yeast, independent of protein modification by Urm1 (18).
UFC1
UFC1 (also known as HSPC155) is an UFM1-conjugating E2
enzyme consisting of 167 amino acids with a predicted mol-
ecular mass of 19.4 kDa. Its gene is located in human chro-
mosome 1q23.3. UFC1 is mainly localized in the nucleus and
partly in the cytoplasm, but excluded from the nucleoli (http:
//www.proteinatlas.org). UFC1 shows low sequence homology
(within a range of 13–17%) with other E2 enzymes (23). How-
ever, UFC1 has the catalytic core domain conserved in all E2-like
enzymes, except that it contains an additional N-terminal helix.
The active site Cys116 is located in a flexible loop that is highly
solvent accessible. Upon binding of UFC1 to the ubiquitin-fold
domain of UBA5, UFM1 is transferred to the cysteine residue of
UFC1 by a transesterification reaction.
The neuronal cell adhesion molecule (NCAM) plays important
roles in the control of cell migration, synaptogenesis, and axonal
outgrowth (24). Recently, NCAM140, an isoform of NCAM, was
shown to interact with UFC1 upon analysis by protein macro-
array and ELISA (24). NCAM140 and UFC1 co-localize in the
surface of B35 neuroblastoma cells and overexpression of UFM1
increases NCAM140 endocytosis. Therefore, UFM1 has been sug-
gested to play a role in trafficking of cell surface molecules,
although it remains unknown whether NCAM140 or other cell
surface proteins are modified by UFM1.
UFL1
UFL1 (also known as Maxer, NLBP, and RCAD) is an UFM1 E3 lig-
ase consisting of 794 amino acids with a predicted molecular mass
of 89.5 kDa. Its gene is located in human chromosome 6q16.1.
UFL1 has a transmembrane domain and localizes predominantly
in ER membrane. It also has a nuclear localization signal (NLS)
sequence, which is functional only when the transmembrane
domain is deleted (25, 26).
UFL1 does not have any domain conserved for ubiquitin E3
ligases, such as HECT, RING finger, and U-box. However, its
N-terminal region (amino acid sequence: 1–202) is highly con-
served across species, and sufficient for the transfer of UFM1 from
UFC1 to C20orf116, the first target substrate identified for ufmy-
lation, under both in vitro and in vivo conditions (26). Since the
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N-terminal region lacks the active site cysteine residue, which
is typically found in HECT type E3 ligase for transthiolation
reaction, UFL1 may play a role as a scaffold protein that recruits
E2 enzyme and target proteins similarly to RING type ubiquitin
E3 ligase.
UFBP1
UFM1-binding protein 1 (UFBP1: also known as Dashurin and
DDRGK1) consists of 314 amino acids with a predicted molecular
mass of 35.6 kDa. Its gene is located in human chromosome 20q13.
UFBP1 contains a transmembrane helix (amino acid sequence:
4–21), a NLS sequence (64–68), a PCI [proteasome, COP9, and
initiation factor domain (228–272)], and a DDRGK sequence
(253–267) (27). UFBP1 also has an N-terminal signal sequence (1–
26) for its localization in ER. However, deletion of the N-terminal
signal sequence leads to nuclear localization of UFBP1.
UFBP1 was originally identified as C20orf116, which is the first
target protein identified for ufmylation (26). It interacts not only
with UFM1 but also with UFL1 and target proteins for ufmylation,
such as ASC1 and LZAP. Depletion of UFBP1 abrogates ufmylation
of the target proteins, indicating that UFBP1 serves as a cofactor as
well as a substrate for ufmylation. Interestingly, ASC1 ufmylation
could also be prevented by substitution of the UFM1 acceptor site
Lys267 in UFBP1 with Arg. Moreover, this Lys-to-Arg mutation
markedly reduces the interaction of UFBP1 with UFL1, although
not with ASC1. Thus, it appears that UFBP1 may first act as a
substrate of UFL1 through their weak binding and the ufmylated
UFBP1, then binds to the ligase with high affinity, which might
be required for the activation of UFL1. Figure 2 summarizes the
overall process of protein ufmylation.
FIGURE 2 | Pathway for protein modification by UFM1. Matured UFM1
generated from its precursor by UFSP2 is activated by UBA5 (E1),
transferred to UFC1 (E2), and then conjugated to target substrates by UFL1
(E3) with the aid of UFBP1. This ufmylation pathway can be reversed by
USFP2. “S ~” indicates the thioester bond.
UFM1-SPECIFIC PROTEASES
UFSP1
Mouse Ufsp1 consists of 217 amino acids with a predicted molecu-
lar mass of 23.4 kDa. Like most deubiquitinating enzymes (DUBs)
and ubiquitin-like protein-specific proteases (ULPs), mouse Ufsp1
belongs to the family of cysteine proteases. However, it shows
no sequence homology to previously known proteases (28). This
novel cysteine protease has a papain-like fold with a unique active
site that is composed of a Cys box and a conserved “Asp-Pro-
His”box, instead of the canonical Cys-His-Asp catalytic triad. This
novel active site configuration appears to form a new subfamily of
the cysteine protease superfamily (28).
Human USFP1 consists of 142 amino acids with a predicted
molecular mass of 15.0 kDa. Its gene is located in human chromo-
some 7q22.1. However, unlike the catalytically active mouse Ufsp1,
human UFSP1 is expected to be non-functional, since it is shorter
on the N-terminus and thereby lacks the conserved cysteine active
site (Figure 3).
UFSP2
Human USFP2 consists of 469 amino acids with a predicted mole-
cular mass of 53.16 kDa. Its gene is located in chromosome 4q35.1.
The crystal structure of mouse UFSP2 shows that the protease is
composed of two domains (29). The C-terminal catalytic domain
is similar to UFSP1 with the active site composed of a Cys box
and a conserved Asp-Pro-His box. The novel N-terminal domain
shows a unique structure and plays a role in the recognition
of UFBP1. UFSP2 resides in both the nucleus and the cyto-
plasm. However, overexpressed N-terminal domain co-localizes
with UFBP1 in ER, where UFBP1 predominantly localizes, sug-
gesting that the N-terminal domain of UFSP2 plays an important
role in the recruitment of UFBP1 to ER for reversal of ufmylation
process.
A mutation within the human UFSP2 gene has been identified
in a family with an autosomal dominant form of hip dysplasia,
called Beukes familial hip dysplasia (29). This mutation predicts
the replacement of the highly conserved Tyr290 by His in the
encoded protein. Interestingly, the substitution of Tyr282 in mouse
UFSP2, which is equivalent to Tyr290 in human UFSP2, abolishes
the in vitro UFM1-processing activity (22). Thus, it appears that
impairment of reversible modification of unknown protein(s) by
UFM1 is associated with an autosomal dominant form of hip
dysplasia.
FIGURE 3 | Schematic diagram for primary structures of UFBPs. “C”
and “DPH” denote the active site Cys-box (red) and Asp-Pro-His box
(orange), respectively. Note that hUFSP1 lacks the Cys box.
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ROLE OF ASC1 UFMYLATION IN BREAST CANCER
DEVELOPMENT
IDENTIFICATION OF ASC1 AS A TARGET FOR UFMYLATION
Although UFBP1 (C20orf116) was identified as the first tar-
get protein for ufmylation (26), its biological function remained
unknown. Recently, however, numerous target proteins for ufmy-
lation have been identified by stable expression of Flag-His-
UFM1 in NIH3T3 and double affinity purification using Ni2+-
nitrilotriacetic acid-conjugated agarose and anti-Flag antibody-
conjugated resins, followed by mass spectrometry (22). The iden-
tified ufmylated proteins include ASC1, a transcriptional coacti-
vator of ERα, and LZAP (also known as CDK5RAP3 and C53)
that has tumor suppressive functions, including activation of
p53, induction of apoptosis, and suppression of NF-κB signaling
(30–32).
All of Lys324, Lys325, Lys334, and Lys367 in ASC1 serve as the
acceptor sites for UFM1 (22). Of the six lysine residues in UFM1,
only Lys69 is involved in poly-UFM1 chain formation on ASC1 via
isopeptide bond linkage. However, it is possible that other lysine
residues may also participate in poly-UFM1 chain formation on
other target proteins. Knockdown of any of UBA5 (E1), UFC1
(E2), UFL1 (E3), and UFBP1 abrogates poly-UFM1 chain forma-
tion on ASC1, indicating that UFBP1 serves as an essential cofactor
for ufmylation process.
REQUIREMENT OF ESTROGEN FOR ASC1 UFMYLATION
Endogenous ASC1 can be ufmylated upon treatment of ERα-
negative cells with estrogen, but not without it (22). In the absence
of estrogen, UFSP2 remains bound to the N-terminal zinc-finger
domain of ASC1, and rapidly removes UFM1 molecules that are
conjugated to ASC1. In the presence of the hormone, ERα forms a
dimeric complex, translocates to the nucleus, and displaces UFSP2
for its binding to the zinc-finger domain of ASC1, thus allowing
ASC1 ufmylation. On the other hand, no ufmylation of ASC1 can
be observed in ERα-negative cells, such as MDA-MB-453, regard-
less of the presence of estrogen. In addition, 4-hydroxy-tamoxifen,
an ERα antagonist, abrogates ASC1 ufmylation by preventing the
interaction of ASC1 with ERα, indicating the requirement of
estrogen binding to ERα for ASC1 ufmylation.
ASC1 acts as a general transcriptional co-activator of nuclear
hormone receptors upon binding to not only ERα but also
other nuclear receptors, such as androgen receptor (AR) (15).
Accordingly, dihydrotestosterone (DHT), an AR agonist, induces
ASC1 ufmylation in LNCap (AR-positive) cells, but not in PC3
(AR-negative) cells (22). Thus, ligand-dependent ASC1 ufmy-
lation appears specific to cognate nuclear hormone receptors
and it is likely that ligands for other nuclear receptors (e.g.,
all-trans-retinoic acid for RARα) can induce ASC1 ufmylation.
REQUIREMENT OF ASC1 UFMYLATION FOR ERα TRANSACTIVATION
The zinc-finger domain of ASC1 serves as a binding site for nuclear
hormone receptors, transcriptional co-activators (e.g., SRC1 and
p300), and basic transcriptional machinery (e.g., TFIIA and TBP)
(14). Thus, ASC1 plays an important role as a platform that
recruits the necessary components for nuclear receptor-mediated
transcription. However, it remained unclear how the zinc-finger
domain, a short region in ASC1 (amino acid sequence: 125-237),
can simultaneously interact with such a group of the proteins.
Remarkably, poly-UFM1 chain conjugated to ASC1 plays a cru-
cial role as a scaffold protein that recruits SRC1, p300, ERα,
and ASC1 itself to estrogen-responsive elements (EREs) located
in the promoters of ERα target genes, such as pS2, Cyclin D,
and c-MYC (22, 33, 34). Moreover, this recruitment leads to a
dramatic increase in ERα transactivation. Whereas knockdown
of UFSP2 markedly promotes ERα transactivation, its overex-
pression abolishes it. Knockdown of UBA5 or overexpression of
an ufmylation-deficient ASC1 mutant, in which the four UFM1
acceptor lysine residues are replaced by arginine, also abrogates
ERα transactivation, indicating that ASC1 ufmylation is crucial
for ERα transactivation.
PROMOTION OF TUMOR FORMATION BY ASC1 UFMYLATION
Recently, colony-forming assay has shown that estrogen-induced
ASC1 ufmylation is critically involved in anchorage-independent
growth of ERα-positive MCF7 breast cancer cells (22). Xenograft
analysis using ovariectomized mice has further revealed that ASC1
ufmylation is tightly associated with estrogen-dependent tumor
formation in vivo (22). Whereas depletion of ASC1, UBA5, or
both prevent colony formation and tumor growth, overexpres-
sion of ASC1 markedly increases them. Remarkably, depletion of
UFSP2 most dramatically promotes the cell growth and tumor
formation, and this promotion can be abrogated by simultane-
ous depletion of ASC1, implicating the role of UFSP2 as a tumor
suppressor. In addition, tamoxifen could completely reverse the
stimulatory effects of ASC1 overexpression and UFSP2 depletion
on colony formation and tumor growth. These findings impli-
cate a crucial role of ASC1 ufmylation in development of ERα-
positive breast cancer by promoting ERα transactivity. Figure 4
summarizes estrogen-induced ASC1 ufmylation pathway for ERα
transactivation, which leads to development of breast cancer.
POSSIBILITY FOR DEVELOPMENT OF ANTI-BREAST CANCER DRUG
Breast cancer is one of the most prevailing cancers of woman.
It is well-known that estrogen plays a critical role in the patho-
genesis and development of breast cancer (35). Moreover, nearly
70% of breast cancer is ERα-positive (36). Therefore, patients with
ERα-positive cancer have been treated with aromatase inhibitors,
which prevent the synthesis of estrogen or with tamoxifen, which
blocks the binding of estrogen to ERα (35–38). These treat-
ments are highly effective, but many patients inevitably develop
the drug-resistant invasive tumors. Therefore, new drugs against
ERα-positive breast cancer are of high demand.
As to the findings that estrogen-induced ASC1 ufmylation is
required for ERα transactivation and tumor formation (22), UBA5
and other components of UFM1-conjugating machinery involved
in ASC1 ufmylation could be used as potential targets for develop-
ment of new therapeutic drugs against ERα-positive breast cancer.
Significantly, the induction of ASC1 ufmylation is not limited to
estrogen, but could also occur in the presence of other ligands,
such as testosterone and retinoic acid, if their cognate nuclear
receptors are present in cells (22). Thus, the components of UFM1-
conjugating system may also represent potent therapeutic targets
in patients with other nuclear receptor-related cancers, such as
prostate and leukemic cancers. Since UFSP2 knockdown leads
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FIGURE 4 | Pathway for estrogen-induced ASC1 ufmylation for ERα
transactivation. “DRUG” indicates any small molecule that can act as a
therapeutic anti-breast cancer drug by blocking ASC1 ufmylation.
to the most dramatic effect on the increase in cell proliferation,
anchorage-independent colony formation, and tumor formation,
small molecules that increase the affinity of UFSP2 to the zinc-
finger domain of ASC1, or the activity of the protease could also
be used as a potential drug against the nuclear receptor-mediated
cancers.
OTHER BIOLOGICAL FUNCTIONS OF THE
UFM1-CONJUGATING SYSTEM
UFL1 IN TUMORIGENESIS
The human UFL1 gene is located in chromosome 6q16.1, a region
that was reported to be frequently lost in prostate and gastric can-
cers as well as in bile duct cancer cell lines (39–41). It has also been
reported that the expression of UFL1 (also called NLBP, RCAD,
and Maxer) cannot be detected in invasive hepatocellular carci-
noma cells including HepG2, Hep3B, HLE, and PLC, whereas it
can be detected in non-invasive Huh7 hepatocellular carcinoma
cell line (39). In addition, UFL1 was shown to cooperate with
LZAP in suppression of cell invasion and NF-κB signaling by
mutual stabilization, suggesting that UFL1 may act as a tumor
suppressor (27).
However, it has also been reported that UFL1 knockdown sup-
presses the proliferation of C6 glioma cells and LZAP-mediated
inhibition of Cyclin D1 transcription (25). In addition, UFL1 is
highly expressed in human lung adenocarcinoma and its overex-
pression promotes the proliferation of rat H1299 lung cancer cells
through interaction with p120 catenin, suggesting that UFL1 may
play a role in development of lung carcinoma (42). Thus, UFL1
seems to have two opposite functions: one in tumor suppression
and the other in tumor development, perhaps depending on its tar-
get proteins for ufmylation in different types of cells and tissues.
In this respect, it would be of high interest to see if UFL1-mediated
ufmylation differentially influences the function of LZAP and p120
catenin in the control of tumorigenesis, although it is also possible
that UFL1 may regulate their functions independently of its E3
ligase activity.
Interestingly, UFBP1 was shown to bind to I-κB, stabilize it, and
thereby inhibit NF-κB signaling (43). In addition, UFBP1 knock-
down leads to inhibition of cell migration and invasion. Thus,
UFBP1, like UFL1, plays two opposite roles as a tumor suppressor
by inhibiting NF-κB signaling and as a tumor promoter by serv-
ing as a cofactor of the UFM1-conjugating system for ASC1 in
development of breast cancer. UFBP1 may regulate NF-κB path-
way independently of its cofactor function in ufmylation. Further
studies are required to clarify the opposite dual functions of UFBP1
and UFL1 in the control of tumorigenesis and NF-κB signaling.
THE UFM1 SYSTEM IN ER STRESS RESPONSE
The expression of UFM1 was shown to be up-regulated in type
2 diabetes and ischemic heart disease in mice, whose pathologi-
cal conditions are associated with activation of ER stress response
(44–47). ER stress induced by cyclopiazonic acid or thapsigargin,
both of which are inhibitors of the ER Ca2+ATPase pump, was also
shown to increase the expression of UFM1, UFBP1, and UFL1 (48).
Interestingly, this increase attenuates ER stress-induced apopto-
sis of mouse pancreatic β-cells. Recently, brefeldin, an inhibitor
of vesicle trafficking, has been shown to increase the transcript
level of UFM1, UFBP1, and UFL1, and this increase could not
be observed in Xbp1-/- MEFs (45). These findings suggest that the
UFM1-conjugating system plays an important role in maintaining
the ER homeostasis.
CONCLUDING REMARKS
The UFM1-conjugating machinery, consisting of UBA5 (E1),
UFC1 (E2), UFL1 (E3), and UFBP1, is the most recently discovered
post-translational protein modification system, whose biological
function is largely unknown. Intriguingly, estrogen-induced ASC1
ufmylation by this system plays a crucial role in development
of breast cancer by promoting ERα-transactivation. Thus, each
component of the UFM1-conjugating machinery and UFSP2 that
reverses ufmylation process could be potential targets for devel-
opment of drug against ERα-positive breast cancer. Since ASC1
ufmylation can be achieved by specific ligands for other nuclear
receptors, such as AR and RARα, it would be of interest to examine
whether ASC1 ufmylation also promotes the transcriptional activ-
ity of the nuclear receptors and thereby the receptor-mediated
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cancers, such as prostate and leukemic cancers, respectively. Up to
present, however, the knowledge on biological function of protein
ufmylation is limited to ASC1. Significantly, ER stress induces the
expression of UBA5, UFBP1, and UFL1, suggesting that proteins
involved in UPR response may be potential targets for ufmylation.
Thus, extensive studies are of necessity to identify more target
proteins for ufmylation and explore their biological function.
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